Garrido, Carolina <br/><br/>
Mechanisms involved in CD4 cell gains in HIV-infected patients switched to raltegravir.  [electronic resource] 

 -  AIDS (London, England)  Mar 2012 
 - 551-7 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1473-5571 
<br/><br/><label>Standard No.: </label>10.1097/QAD.0b013e3283509826  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>ADP-ribosyl Cyclase 1--drug effects<br/>Adult<br/>Antiretroviral Therapy, Highly Active--methods<br/>CD4 Lymphocyte Count<br/>Case-Control Studies<br/>Fas Ligand Protein--drug effects<br/>Flow Cytometry<br/>HIV Infections--drug therapy<br/>HIV Integrase Inhibitors--therapeutic use<br/>Humans<br/>Leukocyte Common Antigens--drug effects<br/>Middle Aged<br/>Platelet Endothelial Cell Adhesion Molecule-1--drug effects<br/>Pyrrolidinones--therapeutic use<br/>Raltegravir Potassium<br/>TNF-Related Apoptosis-Inducing Ligand--drug effects<br/>Treatment Outcome<br/>Tumor Necrosis Factor Receptor Superfamily, Member 7--drug effects